Abstract: The invention provides GLP-1 compounds coupled to al leasl one polyethylene glycol molecule.or derivative thereof, resulting in a biologically active peplide with an extended haif-life and a slower clearance when compared to that of unPEGylaied peplidc. These PEGyJated OLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering pjasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric anoVor infesimal emptying, or inhibiting food intake.
| # | Name | Date |
|---|---|---|
| 1 | 01611-kolnp-2005-abstract.pdf | 2011-10-07 |
| 1 | 01611-kolnp-2005-international publication.pdf | 2011-10-07 |
| 2 | 01611-kolnp-2005-claims.pdf | 2011-10-07 |
| 2 | 01611-kolnp-2005-form 5.pdf | 2011-10-07 |
| 3 | 01611-kolnp-2005-description complete.pdf | 2011-10-07 |
| 3 | 01611-kolnp-2005-form 3.pdf | 2011-10-07 |
| 4 | 01611-kolnp-2005-form 1.pdf | 2011-10-07 |
| 4 | 01611-kolnp-2005-form 2.pdf | 2011-10-07 |
| 5 | 01611-kolnp-2005-form 1.pdf | 2011-10-07 |
| 5 | 01611-kolnp-2005-form 2.pdf | 2011-10-07 |
| 6 | 01611-kolnp-2005-description complete.pdf | 2011-10-07 |
| 6 | 01611-kolnp-2005-form 3.pdf | 2011-10-07 |
| 7 | 01611-kolnp-2005-claims.pdf | 2011-10-07 |
| 7 | 01611-kolnp-2005-form 5.pdf | 2011-10-07 |
| 8 | 01611-kolnp-2005-abstract.pdf | 2011-10-07 |
| 8 | 01611-kolnp-2005-international publication.pdf | 2011-10-07 |